Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences
- 1Department of Ophthalmology, University of Ulm, Ulm, Germany
- 2Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
- Correspondence to Dr Heidrun L Deissler, Department of Ophthalmology, University of Ulm, Prittwitzstrasse 43, D-89075 Ulm, Germany; heidrun.deissler{at}uniklinik-ulm.de
-
Contributors HLD: planning of research; planning, performing (in part) and analyses of experiments; writing and revision of manuscript, approval of final version. GEL: planning of research; comments on manuscript, approval of final version. HD: writing and revision of manuscript, approval of final version.
- Accepted 5 April 2012
- Published Online First 26 April 2012
Abstract
Background Retinal endothelial cells are crucially involved in the genesis of diabetic retinopathy which is treated with vascular endothelial growth factor (VEGF) inhibitors. Of these, ranibizumab can completely restore VEGF-induced effects on immortalised bovine retinal endothelial cells (iBREC). In most experiments supporting diabetic retinopathy therapy with bevacizumab, only non-retinal EC or retinal pigment epithelial cells have been used. Also, bevacizumab but not ranibizumab can accumulate in retinal pigment epithelial cells.
Objective To investigate the effects of bevacizumab on VEGF-induced changes of iBREC properties and potential uptake and accumulation of both inhibitors.
Methods Uptake of VEGF inhibitors by iBREC with or without pretreatment with VEGF165 was visualised by immunofluorescence staining and western blot analyses. Measured transendothelial resistance (TER) of iBREC (±VEGF165) showed effects on permeability, indicated also by the western blot-determined tight junction protein claudin-1. The influence of bevacizumab on proliferation and migration of iBREC was studied in the presence and absence of VEGF165.
Results Bevacizumab strongly inhibited VEGF-stimulated and basal migration, but was less efficient than ranibizumab in inhibiting VEGF-induced proliferation or restoring the VEGF-induced decrease of TER and claudin-1. This ability was completely lost after storage of bevacizumab for 4 weeks at 4°C. Ranibizumab and bevacizumab were detectable in whole cell extracts after treatment for at least 1 h; bevacizumab accumulated during prolonged treatment. Ranibizumab was found in the membrane/organelle fraction, whereas bevacizumab was associated with the cytoskeleton.
Conclusion Both inhibitors had similar effects on retinal endothelial cells; however, some differences were recognised. Although barrier properties were not affected by internalised bevacizumab in vitro, potential adverse effects due to accumulation after repetitive intravitreal injections remain to be investigated.
- Retinal endothelial cells
- VEGF inhibition
- diabetic macular oedema
- diabetic retinopathy
- biochemistry
- diagnostic tests/investigation
- macula
- neovascularisation
- retina
Footnotes
-
Funding Independent research grant by Novartis Pharma GmbH, Nuremberg.
-
Competing interests Independent research grant by Novartis Pharma GmbH, Nuremberg.
-
Provenance and peer review Not commissioned; externally peer reviewed.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
